Johns Hopkins School of Medicine, 1550 Orleans St, Baltimore, MD 21287, USA.
Trends Mol Med. 2011 Jan;17(1):25-33. doi: 10.1016/j.molmed.2010.10.004. Epub 2010 Nov 9.
The recent past has experienced a renaissance in tuberculosis (TB) research. New molecular biology reagents and genetic tools have been developed and whole genome sequences of Mycobacterium tuberculosis strains are now widely available. An increase in the prevalence of drug-resistant strains of M. tuberculosis has renewed focus on the development of new drugs against this millennia old disease. The identification of new targets in M. tuberculosis that might be inhibited to effectively kill the existing strains is now a global pursuit. This review summarizes recently identified targets in M. tuberculosis that have been validated beyond initial genetic identification. Advancing these defined targets for the development of inhibitors has the potential to produce new drugs with novel mechanisms of actions and benefit TB patients worldwide.
近年来,结核病(TB)研究迎来了复兴。新的分子生物学试剂和遗传工具已经被开发出来,结核分枝杆菌菌株的全基因组序列现在也广泛可用。结核分枝杆菌耐药菌株的流行率增加,再次促使人们关注针对这种存在了数千年疾病的新药研发。目前,全球都在努力寻找结核分枝杆菌中的新靶点,这些靶点可能可以被抑制,从而有效地杀死现有的菌株。这篇综述总结了最近已经过初始遗传鉴定验证的结核分枝杆菌中的已确定靶点。推进这些已定义靶点的抑制剂开发,有可能产生具有新型作用机制的新药,使全球的结核病患者受益。